Rheumatology

The risk for patients with monoclonal gammopathy of undetermined significance developing multiple myeloma is double if they have a specific category of rheumatic diseases compared with those without the diseases.

COVID-19 led many patients to change their use of disease-modifying antirheumatic drugs in the pandemic’s initial months, with or without physician guidance.

Behçet disease (BD), a rare systemic inflammatory disease, is associated with multiple sclerosis (MS) and rheumatoid arthritis (RA).

In patients with chronic inflammatory rheumatic and musculoskeletal diseases (RMD), the presence of metabolic syndrome (MetS) indicates an increased risk of cancer.

The bipartisan bill spells out 5 step therapy exemptions for patients by amending the Employee Retirement Income Security Act of 1974.

As the first quarter of 2021 ends, patients choosing to keep using secukinumab may be offered an inducement to switch to another biologic, ixekizumab.

There is a lack of standards for diagnosing and treating nail psoriasis, a situation needing attention because the condition is often a precursor to psoriatic arthritis.

Five biologics used in the treatment of adult patients with plaque psoriasis have been found to improve health-related quality of life.

More real-world evidence is needed to determine what role a score of 100 on the Psoriasis Area and Severity Index (PASI) might have in daily clinical practice, according to a recent review.

Elderly onset rheumatoid arthritis (RA) can be brought under control with a lower methotrexate (MTX) dosage than that required for young-onset disease.

A recent study found that patients living in an an area with low socioeconomic status were less likely to be prescribed biological disease-modifying antirheumatic drugs if they were considered low-income and were male and African American.

From 1999 to 2015, permanent disability claims for patients with rheumatoid arthritis (RA) spiked during periods of economic recessions, suggesting that the COVID-19 pandemic may create a similar effect in the near future.

The novel systemic-immune inflammation index (SII) can be used to predict the onset of psoriasis.

Multimorbidity affects 1 in 4 US adults and leads to increased health care use and lower quality of life.

The results from an analysis of patients from 12 rheumatology centers treated with secukinumab for psoriatic arthritis were in line with earlier pivotal trials, the researchers said.

Abatacept was shown to have a 9% increase in likelihood of achieving remission compared with conventional therapy for rheumatoid arthritis (RA), which the researchers contribute to the treatment’s lower discontinuation rates.

After 4 weeks of a standard treatment regimen, patients demonstrated a 75% reduction in the Psoriasis Area and Severity Index score (PASI).

A recent study took a look at the use of biologics for generalized pustular psoriasis, a rare, potentially life-threatening inflammatory disorder.

An apparent first case of psoriatic arthritis triggered by coronavirus disease 2019 (COVID-19) was reported in a genetically predisposed patient.

Secukinumab rarely leads to latent tuberculosis infection as a reported adverse event and is supported for use in treating chronic systemic inflammatory conditions.

The American College of Rheumatology (ACR) announced a number of policy priorities that it is encouraging the new Congress and administration to focus on during the year.

The study sought to understand how psoriasis treatments perform in real-world settings.

CMS finalized a rule on electronic data entry that will streamline the prior authorization process and improve data transparency for providers, payers, and patients.

Study findings, published in Frontiers in Medicine, underscore the importance of metabolic profiling for discovering candidate screening biomarkers for interstitial lung disease (ILD) in rheumatoid arthritis.

In an unexpected finding, patients with psoriasis showed similar hand impairment to patients with psoriatic arthritis and rheumatoid arthritis.

A Greek study examined the prevalence of comorbidities in patients with rheumatoid arthritis (RA), diabetes, and psoriatic arthritis (PsA).

Both secukinumab 300 mg and secukinumab 150 mg significantly improved signs and symptoms of axial disease in patients with psoriatic arthritis (PsA) who had inadequate response to non- steroidal anti-inflammatory drugs.

The study showed that that patients with higher disease activity had significantly lower levels of physical activity.

Integrated health system specialty pharmacies provide specialized services to patients, resulting in high rates of adherence to and financial assistance with specialty disease-modifying antirheumatic drugs.

In the real world, the persistence rate with secukinumab to treat psoriatic arthritis was higher than with ustekinumab.